Worldwide, the ability to develop and gain access to necessary medications has been inhibited by the highly expensive and lengthy drug development process. Our Better DNA™ approach can help facilitate new treatment modalities that provide breakthroughs in therapeutic efficacy and safety.
Embedded Controllable Bioreactors (ECB)
The ECB platform leverages the rapid design, construction, and optimization of DNA (UltraVector®) in combination with the RheoSwitch Therapeutic System® (RTS®) to create high-value therapeutics. The RTS® enables in vivo transcriptional regulation of protein expression under control of an orally administered small-molecule ligand. It also allows for the reprogramming of living cell systems, creating enormous potential in a wide range of life sciences challenges and opportunities.
RTS® is in phase 1 clinical trials, and current clinical data have shown an excellent safety profile (No dose-limiting toxicity or maximum tolerated dose identified, no off-target pharmacodynamics observed), combined with tight expression regulation.
“…the ‘second generation’ rational nature of Intrexon’s genetic engineering technology provides the enabling technology necessary to make this goal a practical reality…”
—CEO, Intrexon channel partner
We are seeking partners to collaborate on the development of therapeutic product candidates in specialties such as:
To discuss collaboration opportunities, click the link below to contact us.